Survival of COVID-19 with Multimorbidity Patients

Background: The outbreak of SARS-CoV-2 abruptly disseminated in early 2020, overcoming the capacity of health systems to respond the pandemic. It was not until the vaccines were launched worldwide that an increase in survival was observed. The objectives of this study were to analyse the characteris...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. Bustos-Vázquez, E. Padilla-González, D. Reyes-Gómez, M. C. Carmona-Ramos, J. A. Monroy-Vargas, A. E. Benítez-Herrera, G. Meléndez-Mier
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 infection survival rate hospitalized patients Hidalgo Mexico multimorbidity Medicine R
Acceso en línea:	https://doaj.org/article/0142f979c0ec45bc8cdce947111feb7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0142f979c0ec45bc8cdce947111feb7f
record_format	dspace
spelling	oai:doaj.org-article:0142f979c0ec45bc8cdce947111feb7f2021-11-25T17:43:44ZSurvival of COVID-19 with Multimorbidity Patients10.3390/healthcare91114232227-9032https://doaj.org/article/0142f979c0ec45bc8cdce947111feb7f2021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9032/9/11/1423https://doaj.org/toc/2227-9032Background: The outbreak of SARS-CoV-2 abruptly disseminated in early 2020, overcoming the capacity of health systems to respond the pandemic. It was not until the vaccines were launched worldwide that an increase in survival was observed. The objectives of this study were to analyse the characteristics of survivors and their relationship with comorbidities. We had access to a database containing information on 16,747 hospitalized patients from Mexico, all infected with SARS-CoV-2, as part of a regular follow-up. The descriptive analysis looked for clusters of either success or failure. We categorized the samples into no comorbidities, or one and up to five coexisting with the infection. We performed a logistic regression test to ascertain what factors were more influential in survival. The main variable of interest was survival associated with multimorbidity factors. The database hosted information on hospitalized patients from Mexico between March 2020 through to April 2021. Categories 2 and 3 had the largest number of patients. Survival rates were higher in categories 0 (64.8%), 1 (57.5%) and 2 (51.6%). In total, 1741 (10.5%) patients were allocated to an ICU unit. Mechanical ventilators were used on 1415 patients, corresponding to 8.76%. Survival was recorded in 9575 patients, accounting for 57.2% of the sample population. Patients without comorbidities, younger people and women were more likely to survive.E. Bustos-VázquezE. Padilla-GonzálezD. Reyes-GómezM. C. Carmona-RamosJ. A. Monroy-VargasA. E. Benítez-HerreraG. Meléndez-MierMDPI AGarticleSARS-CoV-2 infectionsurvival ratehospitalized patientsHidalgo MexicomultimorbidityMedicineRENHealthcare, Vol 9, Iss 1423, p 1423 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 infection survival rate hospitalized patients Hidalgo Mexico multimorbidity Medicine R
spellingShingle	SARS-CoV-2 infection survival rate hospitalized patients Hidalgo Mexico multimorbidity Medicine R E. Bustos-Vázquez E. Padilla-González D. Reyes-Gómez M. C. Carmona-Ramos J. A. Monroy-Vargas A. E. Benítez-Herrera G. Meléndez-Mier Survival of COVID-19 with Multimorbidity Patients
description	Background: The outbreak of SARS-CoV-2 abruptly disseminated in early 2020, overcoming the capacity of health systems to respond the pandemic. It was not until the vaccines were launched worldwide that an increase in survival was observed. The objectives of this study were to analyse the characteristics of survivors and their relationship with comorbidities. We had access to a database containing information on 16,747 hospitalized patients from Mexico, all infected with SARS-CoV-2, as part of a regular follow-up. The descriptive analysis looked for clusters of either success or failure. We categorized the samples into no comorbidities, or one and up to five coexisting with the infection. We performed a logistic regression test to ascertain what factors were more influential in survival. The main variable of interest was survival associated with multimorbidity factors. The database hosted information on hospitalized patients from Mexico between March 2020 through to April 2021. Categories 2 and 3 had the largest number of patients. Survival rates were higher in categories 0 (64.8%), 1 (57.5%) and 2 (51.6%). In total, 1741 (10.5%) patients were allocated to an ICU unit. Mechanical ventilators were used on 1415 patients, corresponding to 8.76%. Survival was recorded in 9575 patients, accounting for 57.2% of the sample population. Patients without comorbidities, younger people and women were more likely to survive.
format	article
author	E. Bustos-Vázquez E. Padilla-González D. Reyes-Gómez M. C. Carmona-Ramos J. A. Monroy-Vargas A. E. Benítez-Herrera G. Meléndez-Mier
author_facet	E. Bustos-Vázquez E. Padilla-González D. Reyes-Gómez M. C. Carmona-Ramos J. A. Monroy-Vargas A. E. Benítez-Herrera G. Meléndez-Mier
author_sort	E. Bustos-Vázquez
title	Survival of COVID-19 with Multimorbidity Patients
title_short	Survival of COVID-19 with Multimorbidity Patients
title_full	Survival of COVID-19 with Multimorbidity Patients
title_fullStr	Survival of COVID-19 with Multimorbidity Patients
title_full_unstemmed	Survival of COVID-19 with Multimorbidity Patients
title_sort	survival of covid-19 with multimorbidity patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0142f979c0ec45bc8cdce947111feb7f
work_keys_str_mv	AT ebustosvazquez survivalofcovid19withmultimorbiditypatients AT epadillagonzalez survivalofcovid19withmultimorbiditypatients AT dreyesgomez survivalofcovid19withmultimorbiditypatients AT mccarmonaramos survivalofcovid19withmultimorbiditypatients AT jamonroyvargas survivalofcovid19withmultimorbiditypatients AT aebenitezherrera survivalofcovid19withmultimorbiditypatients AT gmelendezmier survivalofcovid19withmultimorbiditypatients
_version_	1718412024403197952

Survival of COVID-19 with Multimorbidity Patients

Ejemplares similares